Abstracts tagged "glucocorticoids"

Abstract Number: 554 • 2019 ACR/ARP Annual Meeting
Evidence to Guide Glucocorticoid Tapering Is Lacking in RA
Beth Wallace¹, David Wallace ², Akbar Waljee ³ and Daniel Clauw ⁴, ¹Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Division of General Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Over a third of RA patients are managed with long-term oral glucocorticoids (GC), defined as daily GC use for ≥3 months[1]. Due to dose-dependent…
Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Qufei Wu ², Lang Chen ⁴, Fenglong Xie ⁵, Huifeng Yun ⁴ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Gerd R. Burmester¹, Frank Buttgereit¹, Corrado Bernasconi², Jose Maria Alvaro-Gracia³, Nidia Castro², Maxime Dougados⁴, Cem Gabay⁵, Jacob van Laar⁶, J. Michael Nebesky², Attila Pethö-Schramm², Carlo Salvarani⁷, Marc Y. Donath⁸ and Markus R. John², ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, ⁴Université Paris-Descartes, Paris, France, ⁵University Hospitals of Geneva, Geneva, Switzerland, ⁶University Medical Centre Utrecht, Utrecht, Netherlands, ⁷Università de Modena e Reggio Emilia, Modena, Italy, ⁸University Hospital Basel, Basel, Switzerland
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
Abstract Number: 1767 • 2018 ACR/ARHP Annual Meeting
Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis
Vanessa L. Kronzer¹, Daniel Larson², Cynthia S. Crowson^3,4, Kenneth J. Warrington⁵, Steven R. Ytterberg⁵, Ashima Makol⁴ and Matthew J. Koster⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pathology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: This study aimed to characterize the presenting features and outcomes of patients with small- or medium-vessel vasculitis and gastrointestinal perforation. Methods: Using a retrospective…
Abstract Number: 1889 • 2018 ACR/ARHP Annual Meeting
Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population
Beth Wallace^1,2,3, Paul Lin^2,4, Neil Kamdar^2,4, Mohamed Noureldin^2,3,5, Rodney Hayward^2,3,6, David A. Fox¹, Jeffrey R. Curtis⁷, Kenneth Saag⁸ and Akbar Waljee^2,3,9, ¹Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ²University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁶Department of Internal Medicine, Division of General Medicine, Michigan Medicine, Ann Arbor, MI, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama, Birmingham, AL, ⁹Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Glucocorticoids (GC) reduce RA-related disability and joint damage; RA guidelines endorse short term use during DMARD initiation and flares. Long-term high-dose GC exposure (>3…
Abstract Number: 2141 • 2018 ACR/ARHP Annual Meeting
Development of a Pediatric Glucocorticoid Toxicity Index
Paul Brogan¹, Raymond P. Naden², Stacy P. Ardoin³, Jennifer C. Cooper⁴, Fabrizio De Benedetti⁵, Jean-Francois Dicaire⁶, Despina Eleftheriou⁷, Brian M. Feldman⁸, Jon Goldin⁹, Seth E. Karol¹⁰, Eli Miloslavsky¹¹, Fiona Price-Kuehne¹², David Skuse⁹, Constantine A. Stratakis¹³, Nicholas Webb¹⁴ and John H. Stone¹⁵, ¹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁶Pinnacle Inc., Quebec, QC, Canada, ⁷Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁸Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹Psychiatry, Great Ormond Street Hospital / University College London, London, United Kingdom, ¹⁰Oncology, St. Jude's Children's Hospital, Memphis, TN, ¹¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology, Cambridge University Hospitals, Cambridge, United Kingdom, ¹³National Institute of Child Health and Human Development, Bethesta, MD, ¹⁴Pediatrics, Manchester University, Manchester, United Kingdom, ¹⁵Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A Glucocorticoid Toxicity Index app (GTI 2.0) is now used as a clinical trial outcome measure in adults, but glucocorticoid (GC) toxicity issues in…
Abstract Number: 2172 • 2018 ACR/ARHP Annual Meeting
Overuse of Glucocorticoids in Rheumatoid Arthritis: A National Survey of Primary Care Physicians
Beth Wallace^1,2, Akbar Waljee^2,3,4, Arlene Weissman⁵, Tanner Caverly^2,6,7 and Sameer Saini^2,6,8, ¹Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ²University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁴Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, ⁵Research Center at American College of Physicians, Philadelphia, PA, ⁶Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, ⁷Michigan Medicine Department of Internal Medicine, Division of General Medicine, Ann Arbor, MI, ⁸Michigan Medicine Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI
Background/Purpose: Most patients with RA receive oral glucocorticoids (GC) such as prednisone, despite concerns about safety. We sought to evaluate how primary care physicians (PCPs)…
Abstract Number: 2300 • 2018 ACR/ARHP Annual Meeting
Compliance with Screening and Supplementation Guidelines for Glucocorticoid-Induced Osteoporosis, How Bad Did We Do This Time?
John Zawidniak¹ and John Waterman², ¹Rheumatology, University of Connecticut, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a well-established and well-studied phenomenon that is a sequela of the treatment of many inflammatory diseases. Many studies over the…
Abstract Number: 2319 • 2018 ACR/ARHP Annual Meeting
Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
Patrick Webster¹ and Tarun S. Sharma², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) is an under-recognized and under-treated condition. Many long-term glucocorticoid (GC) users never receive therapy to prevent bone loss or are…
Abstract Number: 2327 • 2018 ACR/ARHP Annual Meeting
To Screen or Not to Screen?Dexa Ordering Patterns in SLE Patients Who Take Systemic Glucocorticoids
Sara Baig¹, Smarika Sapkota², Anna K. Shmagel³, Parastoo Fazeli⁴, Jeremiah Menk¹ and Ann Marie O'Connell⁵, ¹University of Minnesota, Minneapolis, MN, ²Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, ³Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵University of Minnesota, MInneapolis, MN
Background/Purpose: High doses of glucocorticoids (GC) are often used in the treatment of Systemic Lupus Erythematous (SLE), however, studies suggest that SLE patients do not…
Abstract Number: 2339 • 2018 ACR/ARHP Annual Meeting
The Patient’s Perspective of Glucocorticoid Use: A Systematic Literature Review of Quantitative and Qualitative Studies
Jonathan Cheah^1,2, Joanna Robson^3,4, Rachel Black^5,6, Susan M. Goodman^7,8, Susan Lester^9,10, Sarah Mackie¹¹ and Catherine Hill^6,12, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Medicine, Weill Cornell Medicine, New York, NY, ³Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ⁴School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁵Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁶Medicine, The University of Adelaide, Adelaide, Australia, ⁷Rheumatology, Weill Cornell Medicine, New York, NY, ⁸Hospital for Special Surgery, New York, NY, ⁹Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁰Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ¹¹NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ¹²The Queen Elizabeth Hospital, Adelaide, Australia
Background/Purpose: Glucocorticoids (GCs) remain widely used and have well documented adverse effects. However, the impact of these adverse effects from the perspective of the patient,…
Abstract Number: 2340 • 2018 ACR/ARHP Annual Meeting
The Impact of Chronic Glucocorticoid Use Amongst Patients with Rheumatoid Arthritis: A Qualitative Study
Jonathan Cheah^1,2, Sarah Young³, Susan M. Goodman^4,5, Catherine Hill^6,7, Susan Beard⁸, Pamela Richards⁹, Sarah Mackie¹⁰, Joanna Robson^11,12 and Iris Navarro-Millán^5,13, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Medicine, Weill Cornell Medicine, New York, NY, ³Binghamton University, Binghamton, NY, ⁴Rheumatology, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷Medicine, The University of Adelaide, Adelaide, Australia, ⁸Patient Research Partner, Adelaide, Australia, ⁹Patient Research Partner, Bristol, United Kingdom, ¹⁰NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ¹¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ¹²School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ¹³Weill Cornell Medicine, New York, NY
Background/Purpose: Glucocorticoids (GCs) have well documented adverse effects. However, the absolute risk and importance of these effects have not been well documented from the perspective…
Abstract Number: 534 • 2018 ACR/ARHP Annual Meeting
Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy?
Gorica Ristic¹, Vesna Subota², Dejana Stanisavljevic³, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Increased insulin resistance and impaired β-cell function have been demonstrated in rheumatoid arthritis (RA). The aim of the study was to analyze the association…
Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Sytske Anne Bergstra¹, Lai-Ling Winchow², Elizabeth Murphy³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, João E. Fonseca⁶, Cornelia F. Allaart¹ and Robert B.M. Landewé⁷, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²University of the Witwatersrand, Johannesburg, South Africa, ³University Hospital Wishaw, Scotland, Wishaw, United Kingdom, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].